Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GTHXNASDAQ:NAMSNASDAQ:RIGLNASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/ANAMSNewAmsterdam Pharma$15.64-13.1%$21.29$15.19▼$27.29$1.72B-0.04556,443 shs682,539 shsRIGLRigel Pharmaceuticals$16.84-4.7%$20.72$7.48▼$29.82$302.15M1.32208,334 shs95,599 shsSPRYARS Pharmaceuticals$12.77-4.7%$12.11$7.55▼$18.51$1.25B1.031.09 million shs1.14 million shs10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTHXG1 Therapeutics0.00%0.00%0.00%0.00%+51.48%NAMSNewAmsterdam Pharma-1.15%-19.68%-16.28%-30.61%-18.59%RIGLRigel Pharmaceuticals-3.02%-3.97%-20.02%+1.61%+32.78%SPRYARS Pharmaceuticals+2.68%+6.10%+27.50%+19.75%+42.55%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGTHXG1 Therapeutics0.4357 of 5 stars1.00.00.03.80.00.00.6NAMSNewAmsterdam Pharma2.4449 of 5 stars3.51.00.00.03.24.20.0RIGLRigel Pharmaceuticals2.5267 of 5 stars3.21.00.00.02.12.51.9SPRYARS Pharmaceuticals3.061 of 5 stars4.60.00.00.01.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGTHXG1 Therapeutics 2.00Hold$4.00-44.06% DownsideNAMSNewAmsterdam Pharma 3.00Buy$43.33177.03% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.80118.59% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.00142.79% UpsideCurrent Analyst Ratings BreakdownLatest GTHX, RIGL, NAMS, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2025SPRYARS PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$30.003/6/2025RIGLRigel PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $55.003/5/2025RIGLRigel PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.003/5/2025RIGLRigel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.003/3/2025NAMSNewAmsterdam PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$41.003/3/2025SPRYARS PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/27/2025NAMSNewAmsterdam PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.002/27/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $42.002/21/2025SPRYARS PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/10/2025SPRYARS PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$40.001/24/2025NAMSNewAmsterdam PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51NAMSNewAmsterdam Pharma$45.56M37.70N/AN/A$3.50 per share4.47RIGLRigel Pharmaceuticals$179.28M1.68N/AN/A($1.64) per share-10.27SPRYARS Pharmaceuticals$89.15M14.05N/AN/A$2.40 per share5.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/ANAMSNewAmsterdam Pharma-$176.94M-$2.60N/AN/AN/AN/AN/AN/A5/14/2025 (Estimated)RIGLRigel Pharmaceuticals-$25.09M$0.94120.8316.03N/A2.46%-14.80%3.03%5/6/2025 (Estimated)SPRYARS Pharmaceuticals-$54.37M$0.08N/AN/AN/AN/A-22.56%-21.82%5/8/2025 (Estimated)Latest GTHX, RIGL, NAMS, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024SPRYARS Pharmaceuticals-$0.04$0.52+$0.56$0.52$15.46 million$86.58 million3/4/2025Q4 2024RIGLRigel Pharmaceuticals$0.30$0.80+$0.50$0.80$57.59 million$57.60 million2/26/2025Q4 2024NAMSNewAmsterdam Pharma-$0.48-$0.95-$0.47-$0.95$3.30 million$12.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGTHXG1 TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGTHXG1 Therapeutics1.342.482.12NAMSNewAmsterdam PharmaN/A10.6110.61RIGLRigel PharmaceuticalsN/A1.961.87SPRYARS PharmaceuticalsN/A12.5612.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGTHXG1 Therapeutics24.21%NAMSNewAmsterdam Pharma89.89%RIGLRigel Pharmaceuticals66.23%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipGTHXG1 Therapeutics6.11%NAMSNewAmsterdam Pharma19.50%RIGLRigel Pharmaceuticals9.04%SPRYARS Pharmaceuticals40.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableRIGLRigel Pharmaceuticals16017.86 million16.02 millionOptionableSPRYARS Pharmaceuticals9098.12 million58.21 millionOptionableGTHX, RIGL, NAMS, and SPRY HeadlinesRecent News About These CompaniesARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Buy" from AnalystsApril 3 at 2:38 AM | marketbeat.comAssuredPartners Investment Advisors LLC Takes $312,000 Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)March 30, 2025 | marketbeat.comSPRY FY2025 EPS Forecast Reduced by Cantor FitzgeraldMarch 27, 2025 | marketbeat.comEquities Analysts Offer Predictions for SPRY FY2025 EarningsMarch 27, 2025 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This YearMarch 26, 2025 | finance.yahoo.comWilliam Blair Brokers Decrease Earnings Estimates for SPRYMarch 25, 2025 | americanbankingnews.comRaymond James Financial Inc. Makes New $6.58 Million Investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)March 24, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for SPRY FY2028 Earnings?March 24, 2025 | marketbeat.comQ1 EPS Estimate for ARS Pharmaceuticals Reduced by AnalystMarch 24, 2025 | marketbeat.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 10,000 Shares of StockMarch 22, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 11.5% - Here's What HappenedMarch 22, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comScotiabank Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)March 22, 2025 | markets.businessinsider.comARS Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesMarch 22, 2025 | msn.comWhy ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 13.63%March 22, 2025 | aaii.comARS Pharmaceuticals reports FY24 EPS 8c, consensus (56c)March 21, 2025 | markets.businessinsider.comARS Pharmaceuticals expects cash to fund operations for at least next 3 yearsMarch 21, 2025 | markets.businessinsider.comARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Beats Estimates By $0.61 EPSMarch 21, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Better-Than-Expected EarningsMarch 21, 2025 | marketbeat.comARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges AwaitMarch 20, 2025 | seekingalpha.comARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call TranscriptMarch 20, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTHX, RIGL, NAMS, and SPRY Company DescriptionsG1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.NewAmsterdam Pharma NASDAQ:NAMS$15.64 -2.36 (-13.10%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Rigel Pharmaceuticals NASDAQ:RIGL$16.84 -0.83 (-4.67%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.ARS Pharmaceuticals NASDAQ:SPRY$12.77 -0.63 (-4.72%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
